| Clinical data | |
|---|---|
| Other names | Propyldebenzergoline |
| Drug class | Dopamine receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C14H22N2 |
| Molar mass | 218.344 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Debenzergoline, or propyldebenzergoline, is a dopamine receptor agonist and partial ergoline. It is an analogue of ergoline in which the A ring of the ergoline ring system has been removed. The drug strongly inhibits prolactin secretion and produces antiparkinsonian effects in rodents. Debenzergoline was first described in the scientific literature by 1980.
The original suggestion by Nichols (1976), that the pyrroleethylamine moiety of the ergots confers dopaminergic properties to drugs of this class was recently experimentally substantiated by Bach et al. (1980), showing that "debenzergoline" (Fig. 4; 6) is a potent dopaminergic stimulant which appears to lack the 5-HT agonistic (or antagonistic) effects seen with many of the ergot derivatives. [...] Fig. 4. Chemical structures of 5-HT (1), 8-OH-DPAT (2), lisuride (3a), LSD (3b), 4-(2-[di-n-propylamino]ethyl)indole (DPAI; 4), 10-OH-octahydrobenzo(f)quinoline (5) and "debenzergoline" (6).